

Depressive disorders in childhood Trastornos depresivos en la infancia

Elva J. Corona-Olivera ^a

Abstract:

Depression is one of the main psychiatric disorders that prevails during childhood and adolescence. The causes are multifactorial, of which the following stand out: traumatic events, the social development environment, genetics and brain chemistry accompanied by some anatomical and functional alterations. The consequences can be serious in the long term and can even contribute to the problem if it is not identified and referred promptly or lead to suicide, once the diagnosis has not been effective. The treatment for depression is complex and includes drugs and cognitive-behavioral therapy. This article aims to help first contact physicians to diagnose in a timely manner to act in situations that may endanger the patient with this condition, and therefore refer to specialists.

Keywords:

Depressive disorder, adolescence, childhood, psychiatric disorder, prevalence.

Resumen:

La depresión es uno de los principales trastornos psiquiátricos que prevalece durante la infancia y la adolescencia. Las causas son multifactoriales, de las cuales resaltan: eventos traumáticos, el entorno social de desarrollo, genética y química cerebral acompañada de algunas alteraciones anatómicas y funcionales. Las consecuencias pueden ser graves a largo plazo e incluso se puede contribuir al problema si no se identifica y se refiere oportunamente o conducir al suicidio, toda vez que el diagnóstico no haya sido eficaz. El tratamiento de la depresión es complejo e incluye fármacos y terapia cognitivo - conductual. Este artículo tiene como objetivo ayudar a los médicos de primer contacto a diagnosticar de manera oportuna para actuar en situaciones que puedan poner en peligro al paciente con esta condición, y por tanto realizar la referencia a especialistas.

Palabras Clave:

Trastorno depresivo, adolescencia, infancia, trastorno psiquiátrico, prevalencia.

INTRODUCTION

Mental health is a field that continues to be studied throughout the history of health in the world, and the interest in it has grown in the last three decades. Depressive disorders are pathologies that are included in this medical branch.¹ Childhood and adolescence are the first stages of life that define certain traits of all human beings.²

About half of the first depressive episodes occur during adolescence,³ early life stressors have been shown to delay brain maturation and lead to poor self-control in early adolescence.⁴ It is believed that some of the psychiatric diseases of childhood and / or adolescence are preventable, on the other hand, it is known that the chemistry and genetics of the brain will also determine its development.⁵

According to the World Health Organization, mental disorders are the main cause of living with disabilities, in the world and depression is the most important disorder with 40.5% in relation to other mental disorders, between 13 - 18 years of age the rate increases, but only 1% receive treatment.⁶ This article aims to

help first-contact physicians to diagnose patients with depression in a timely manner so that they can be adequately referred, which is why we did an extensive search on PubMed and Google Scholar and a detailed reading of various articles on childhood depression, combining the most relevant data found.

DEFINITION

Psychiatry is the medical specialty that studies mental illnesses, their types, causes, courses, and treatments, while pedopsychiatry is synonymous with child psychiatry and deals with mental disorders in children.¹

The Convention on the Rights of the Child defines a child or infant as any person under 18 years of age, and childhood is the period of life between 0 and 12 years of age, and adolescence between 12 and 18 years of age, who build their identities based on their social, cultural and economic location, in the community and in intra and intergenerational relationships.⁷ Mental health is the state of emotional, cognitive and behavioral balance that allows the individual to function responsibly in

^a Corresponding author, Consultorio particular, <https://orcid.org/0000-0002-8985-703X>, Email: co233150@uaeh.edu.mx

their family, social and work environment, as well as to enjoy well-being and quality of life.¹ Mental disorder: it is the emotional, cognitive alteration and / or behavior in which basic psychological processes such as emotion, motivation, consciousness, behavior, perception, learning and language are affected, making it difficult for the person to adapt to the cultural and social environment in which they live in, generating some form of subjective discomfort.^{1,6}

Depression is characterized by the persistent presence of sadness or depressed mood and the loss of interest in pleasant activities and even the inability to carry out daily activities, for a period of at least two weeks "almost every day".⁶

CLASSIFICATION

The DSM-5 manual (Diagnostic and Statistical Manual of Mental Disorders) classifies depressive disorders as follows:⁸

Major depressive disorder (often called depression)

- Persistent depressive disorder (dysthymia)
- Other specified or unspecified depressive disorder
- Premenstrual Dysphoric Disorder (PMDD)
- Depressive disorder due to another illness
- Substance/drug-induced depressive disorder

ICD-11 contains a section where it classifies mental, behavioral or neurodevelopmental disorders, within which are mood disorders, and in turn contains depressive disorders which are:⁹

1. Single episode depressive disorder

- Mild, single episode depressive disorder
- Moderate single episode depressive disorder without psychotic symptoms
- Moderate single episode depressive disorder with psychotic symptoms
- Severe, single episode depressive disorder without psychotic symptoms
- Severe, single episode depressive disorder with psychotic symptoms
- Single episode depressive disorder, unspecified severity
- Single episode depressive disorder, currently in partial remission
- Single episode depressive disorder, currently in complete remission
- Other specified single episode depressive disorder
- Single episode depressive disorder, unspecified.

2. Recurrent depressive disorder.

- Recurrent depressive disorder, current mild episode
- Recurrent depressive disorder, current moderate episode, without psychotic symptoms
- Recurrent depressive disorder, current moderate episode, with psychotic symptoms
- Recurrent depressive disorder, current severe episode, without psychotic symptoms
- Recurrent depressive disorder, current severe episode, with psychotic symptoms

-Recurrent depressive disorder, current episode, unspecified severity

- Recurrent depressive disorder, currently in partial remission
- Recurrent depressive disorder, currently in complete remission
- Other specified recurrent depressive disorder
- Recurrent depressive disorder, unspecified

3. Dysthymic disorder

4. Mixed depression and anxiety disorder

5. Premenstrual dysphoric disorder

6. Other specified depressive disorders

7. Unspecified depressive disorders

EPIDEMIOLOGY

The prevalence of depression varies according to the sample studied, diagnostic criteria, sources of information, ethnicity and culture,¹⁰ and according to the WHO it is the main mental disorder worldwide.⁶

A study carried out in the United States in 1994 revealed that the prevalence of depression ranges between 0.4% and 2.5% in children and between 0.4% and 8.3% in adolescents.¹¹

In 1995, there was a suicide rate of 0.5 for women and 0.9 for men between 5 - 14 years old, who suffered from a psychiatric disorder.¹²

Among the comorbidities associated with depression, we find post-traumatic stress syndrome (EPS), anxiety and stress, the prevalence of EPS has been recorded in a highly variable way and ranges between 21 - 94%.¹³

On the other hand, adolescent-onset depression is more likely to be associated with alcohol dependence and abuse than when depression begins in adulthood.¹⁴

A quarter of adolescent's present subtle depressive symptoms that alter their daily life, increase the risk of substance use and suicide rates, as well as a deterioration in school performance.^{15,16}

Surveys conducted in Ethiopia revealed a prevalence of childhood depression of 1%¹⁷ and up to 2% in Western countries.¹⁸

Two studies conducted in Mexico by "Benjet C."^{19,20} revealed that there is an incidence of 4.8 - 13% for major depressive disorder in adolescents between 12 and 17 years old, the prevalence by gender is 15.1% for women and 9% for men.^{19,20} Of the population born and residing in Mexico until adulthood, 3.3% suffer from depression, and in the Mexican population that was born or lives in the United States before adulthood, the rate increases to 6.9%.²¹

Another epidemiological study showed that from 1990 to 2000 the suicide rates in children and adolescents between 5 - 14 years of age in Mexico increased from 0.2% to 0.5%²² and that 11.3% of them had had suicidal ideas and up to 3.1% had had a try.²³

Regarding age, a prevalence of 0.03 - 1.9% is estimated for school-age children^{24,25} and 0.7 - 7% for adolescents.²⁶ According to data from INEGI in 2017 in Mexico, 14.5% of children between 7 - 14 years old had felt depression while

among adolescents between 15 - 29 years old it was registered in 25.8%,²⁷ and in 2020 there were 7,896 deaths by suicide at the national level, of which 1160 correspond to children and adolescents between 10 - 19 years of age.²⁷

When inquiring about depression according to gender, we found that women are almost twice as likely to suffer from depression, the prevalence corresponds to 1.8% for men and 2.4% for women, the gaps are smaller at younger ages, girls do have a higher incidence depression, but the gap increases from adolescence, where much more prevalence is observed in women, however, they have a lower degree of remission or chronicity.^{21, 28}

Over the past 3 decades, the incidence of depression has steadily increased and the age of onset has decreased.²⁹

Children or adolescents with depression who present symptoms of anxiety represent between 28 - 56%, so it is not yet clear whether anxiety and depression have a similar or even the same etiology.³⁰⁻³²

CLINICAL SYMPTOMS

The patient may appear tired, preoccupied with himself, bored, inattentive and with little interest in his surroundings,³³ there may also be muscle tension, continuous movement of the hand, repeated crying, use phrases that express sadness or misery, these symptoms may be isolated or present several of them at the same time.³⁴

Physically there is tachycardia, dry tongue / mouth, clammy and / or cold palms, clammy body extremities, paleness, pupillary dilation, tremors, and fluctuations in blood pressure with wide pulse pressure.³⁵

In children, the language to express their emotions is not always broad and trained, so the symptoms are more behavioral than verbal and the vegetative symptoms are recognizable.³⁶

Depressive symptoms tend to be more severe in youth with comorbid anxiety compared to non-anxious youth.³⁷

Depression in childhood and adolescence is characterized by persistent and generalized central sadness, anhedonia, boredom, and irritability, which become functionally disruptive and relatively insensitive to good experiences and interaction with other people.³⁸

Major depression is characterized by a sad or irritable mood or anhedonia (which is the inability to feel pleasure) along with at least five other symptoms, such as social withdrawal, worthlessness, guilt, suicidal thoughts or behavior, increased or decreased sleep, decreased motivation or concentration and increased or decreased appetite.^{27,39}

In adolescence, depressive disorders significantly increase the risk of suicide and the incidence of suicide attempts.⁴⁰ Although young children also tend to have suicidal ideation, they rarely act on it.²⁹

Depression in children is manifested by auditory command or persecutory hallucinations, rather than delusions as seen in adolescents and adults, and is attributed to a lack of cognitive maturation in children,⁴¹ some children report somatic

complaints such as headaches, or stomachaches, anxiety about separation from parents, agitation, fatigue, insomnia, the difficulty to concentrate is the same for infants and adolescents.²⁹

PHYSIOPATHOLOGY

A multifactorial model is acknowledged to explain the depression pathogenesis, it includes genetic, neurobiological, psychosocial, sociocultural, somatic, and familial factors.⁴²

It is assumed 20% risk illness for child whose parents are already ill; if both parents are depressed, the risk increases 50%.⁴³

There is evidence that stressful life events and genetic diathesis, such as a shorter allelic form serotonin transporter, may interact and cause early-onset depression.⁴⁴

Agents that stimulate the serotonergic system cause the release of prolactin and cortisol.³⁸

Some autopsy research and computed tomography studies have shown a reduction in the number of serotonin receptors in the midbrain and amygdala in depressed patients, as well as a reduction in presynaptic and postsynaptic subtypes (also located in the midbrain) of 5HT receptor in patients with depression.^{45,46}

Concentrations of corticotropin-releasing factor and thyrotropin-releasing hormone in the cerebrospinal fluid of untreated depressed patients are higher compared to healthy patients, whereas somatostatin concentration is lower in cerebrospinal fluid of patients with major depressive disorder and bipolar disorder.³⁸

The hypothalamic-pituitary-adrenal axis (HPA) is the main neuroendocrine stress response system, and shows dysfunctional responses to hormone challenges and stress factors, stress-induced abnormalities of HPA could have from longer duration, depending on the length and type of stress, either psychological or physical.⁴⁷

One of the most important factors is the age of the individual, during exposure to the stressor, this means that when stress is caused in the early stages of human development, which is a time of high neural plasticity, dysfunction can develop long-term of the HPA axis and carry it into adulthood,⁴⁷ also during adolescence there is a high release of hormones, especially in women, so that age becomes a determining factor for the condition.³⁸

It is known that several neurotransmitter systems are involved in depression, but that no neurotransmitter system is the only one responsible, it has been possible to observe alteration in the size or volume of some brain structures such as; decreased nucleus of the hippocampus and caudate nucleus, and increased pituitary volume.⁴⁸

There is a theory that speaks of dopamine and anhedonia deficiency and in turn it is one of the main symptoms of depression, therefore, it is believed that there is a close relationship between dopamine deficiency and depression, and studies with drugs have also been carried out that enhance dopamine neurotransmission with which a better response to depression has been observed.⁴⁹

DIAGNOSTIC

Depression screening relies on use of depression symptom assessments, or small questions sets about depression, to identify patients who may be currently depressed, but who have not sought treatment and whose depression has not yet been clinically recognized.⁵⁰

The President's New Freedom Commission on Mental Health in 2003 called for screening in primary health care, schools, and their environments.⁵¹

In Mexico, the Miguel Hidalgo Model was launched, within which it stands out to provide mental health care in health centers, to have greater coverage, which has been put into practice in the State of Hidalgo since 2002.⁵²

For the initial diagnostic evolution there are some tests that can be used:

- Children’s Depression Inventory (CDI) for children and adolescents from 7 to 17 years old.
- Children’s Depression Scale (CDS) from 8 to 14 years old.
- Patient Health Questionnaire-Adolescent version (PHQ-A) aged 13-18 years specifically for use in primary care.
- Child Behavior Checklist (CBCL) for 4 to 18 years.⁵³

According to DSM-5, a depressive disorder will be considered when there is one or more major depressive episodes and the absence of mania and hypomania. The criteria for major depression are:

- Five or more of the nine symptoms (Table 1) are present for a period of at least 2 weeks. One of these symptoms must be depressed mood or anhedonia (loss of interest or pleasure). The frequency required is over a period of 2 weeks, it varies a little depending on the symptom, but the majority should be present "almost every day".

Table 1. Symptoms⁸

Depression symptoms	
1	Depressed state of mind for most of the day.
2	Decreased interest or pleasure in all or almost all activities for most of the day.
3	Significant weight gain or loss (> 5%), or decreased or increased hunger
4	Insomnia or hypersomnia
5	Agitation or psychomotor retardation observed by others (not self-reported)
6	Fatigue or energy loss
7	Feelings of worthlessness or excessive or inappropriate guilt.
8	Decreased ability to think or concentrate, or indecisiveness.
9	Recurrent suicidal or death thoughts, attempt or ideation to commit suicide.

- The symptoms cause distress or significant impairment.
- The episode is not attributable to a substance or disease.

-The episode is not explained by any other psychotic disorder such as: schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder or other psychotic disorder.

-There is no history of having had a non-substance-induced manic or hypomanic episode.⁵⁴

PREVENTION

Given the prevalence of depressive and anxiety disorders in children and adolescents, and their effect at the psychosocial level, programs have been developed for their prevention, which are based on cognitive-behavioral therapy that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes.⁵⁵ Almost all prevention studies focus on reducing depressive symptoms rather than preventing diagnosed depressive episodes.⁵⁶

Prevention strategies increase awareness and reduce stigmatization among children by identifying emotional problems, in addition to depression, these programs also reduce anxiety symptoms.^{57,58}

First contact doctors must identify patients with depression problems, refer them promptly, offer comfort and listen to the patient if there is a risk of damaging their integrity, until they can be treated by the specialist, for a better understanding we created Figure 1 showed below.

Selective preventive interventions are for those groups at risk of developing the disorder, and biological, psychological or social risk indicators are used for their identification to properly select candidates.⁵⁹

TREATMENT

There are more than 150 studies on treatment for depression, including behavioral therapy, interpersonal therapy, psychotherapy, psychodynamics, and more.⁴⁸


Cognitive-behavioral therapy has been shown to effectively treat various psychological disorders in childhood, such as depression, obsessive compulsive disorder, anxiety, school and social phobia, etc.⁶⁰

The severity of depression appears to be the main predictor for determining the efficacy of psychotherapy.^{61,62} According to the available evidence of SSRI (Selective Serotonin Reuptake Inhibitor) in pediatric depression, it is one of the main drugs that have shown true effects over placebo.⁶³⁻⁶⁶

Pharmacological treatment combined with psychotherapy is the treatment with the most scientific evidence.⁶⁷

In the last 20 years, research on childhood and adolescent depression has progressed widely, and more evaluation instruments have been validated, the most studied and extensive therapy is cognitive-behavioral therapy,⁶⁸ and it has also proven to be the most effective therapy, since it teaches children to identify undesirable or maladaptive behaviors, which are determined by negative thoughts, that is, the objective is to modify behavior by identifying and analyzing maladaptive thoughts and emotions and thus impact on behavior.⁶⁰

Figure 1.
Sequence in patients with depressive symptoms



For either of the two treatments, there is an acute phase, a continuation phase and a maintenance phase, and the most commonly used drug is fluoxetine, which has been shown to reduce the symptoms of depression during the acute phase, as well as prevent relapses, while reducing suicide attempts.⁶⁷ Escitalopram is known to be effective in adolescents, but not in children⁶⁹ and paroxetine was found to be ineffective as a treatment in children and adolescents,⁷⁰ on the other hand, the FDA has only approved fluoxetine in children and adolescents and escitalopram for those over 12 years of age.⁷¹ The acute phase involves the stabilization of dangerous behaviors, and initial evaluation, child maltreatment and other continuous stressors could cause the persistence of depression, its objective is to remit symptoms for at least 2 weeks up to <2 months without symptoms, the continuation phase is > 2 months without depressive symptoms, the maintenance phase will help prevent recurrences in young people with chronic, recurrent or severe depressive disorder.⁷²

FORECAST

Treatment-resistant depression was defined as the lack of response to at least one adequate prior trial (both in dose and duration) of a major class of antidepressants; preventive efforts made in the early stages of childhood development effectively prevent the psychological morbidity and promote good mental health in school-going children.^{73,74}

CONCLUSION

Depression in childhood is a pathology that can have repercussions in adult life, and the damage it causes can lead to death, so it must be treated as an important health problem, like any other disease, to improve quality life of children and adolescents who suffer from it.

REFERENCES

- [1] Bravo MF, Saiz J, Bobes J. Manual del Residente en Psiquiatría (Internet). Madrid: sociedades de psiquiatría; 2010. Available in: http://www.sepsiq.org/file/Publicaciones/Manual_Residente_Psiquiatr%C3%ADa2.pdf. Accessed 17/08/2021.
- [2] Irwin LG, Siddiqi A, Hertzman C. Desarrollo de la Primera Infancia: Un Potente Ecuador (Internet). Who.int; 2007. Available in: https://www.who.int/social_determinants/publications/early_child_dev_ecdkn_es.pdf. Accessed 17/08/2021.
- [3] Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, Severity, and Comorbidity of Twelve-month DSM-IV Disorders in the National Comorbidity Survey Replication (NCSR). Arch. Gen. Psychiatry. 2005;62(6):617-27.
- [4] Duckworth AL, Kim B, Tsukayama E. Life stress impairs self-control in early adolescence. Front. Psychol. 2013;3:608.
- [5] McCrory E, De Brito SA, Viding E. Research review: the neurobiology and genetics of maltreatment and adversity. J. Child Psychol. Psychiatry. 2010;51(10):1079-95.
- [6] Avenevoli S, Swendsen J, He JP, Burstein M, Merikangas K. Major depression in the National Comorbidity Survey-Adolescent Supplement: Prevalence, Correlates, and Treatment. J. Am. Acad. Child Adolesc. Psychiatry. 2015;54(1):37-44.
- [7] Gobierno de Colombia. Política Nacional de infancia y adolescencia 2018-2030 (Internet). Colombia: gobierno de Colombia; 2018. Available in: https://www.icbf.gov.co/sites/default/files/politica_nacional_de_infancia_y_adolescencia_2018_-_2030_0.pdf. Accessed 17/08/2021.
- [8] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). American Psychiatric Publishing, 2013. Available in: <http://www.psychiatry.org/dsm5>. Accessed 17/08/2021.
- [9] CIE-11: for Mortality and Morbidity Statistics (Internet). 2021. Available in: <https://icd.who.int/browse11/l-m/en/#/http%3a%2f%2fid.who.int%2fid%2fentify%2f578635574%2fmms%2fother>. Accessed 05/10/2021.
- [10] Demir T, Karacetin G, Demir DE, Uysal O. Epidemiology of depression in an urban population of Turkish children and adolescents. J. Affect. Disord. 2011;134:168-76.
- [11] Anderson JC, McGee R. Comorbidity of depression in children and adolescents. In: Handbook of Depression in Children and Adolescents. New York: Plenum. 1994;581-601.
- [12] Statistics Finland. Causes of death 2000. Helsinki: Statistics Finland. 2002. Available in: http://www.stat.fi/ti/ksyyt/kas_en.html.
- [13] Ginzburg K, Ein-Dor T, Solomon Z. Comorbidity of posttraumatic stress disorder, anxiety and depression: A 20-year longitudinal study of war veterans. J. Affect. Disord. 2010;123:249-57.
- [14] Alpert JE, Fava M, Uebelacker LA, Nierenberg AA, Pava JA, Worthington III JJ, et al. Patterns of Axis I comorbidity in early-onset versus late-onset major depressive disorder. Biol. Psychiatry. 1999;46:202-11.

- [15] Klein DN, Shankman SA, Lewinsohn PM, Seeley JR. Subthreshold depressive disorder in adolescents: Predictors of escalation to full-syndrome depressive disorders. *J. Am. Acad. Child Adolesc. Psychiatry.* 2009;48(7):703-10.
- [16] Brent D, Weersing VR. Depressive disorders in childhood and adolescence. In: Rutter M, Bishop DVM, Pine DS, Scott S, Thapar A, editors. *Rutter's Child and Adolescent Psychiatry.* Australia:Deirdre Barry;2008:587-613.
- [17] Ashenafi Y, Kebede D, Desta M, Alem A. Prevalence of mental and behavioural disorders in Ethiopian children. *East Afr. Med. J.* 2001;78(6):308-11.
- [18] Harrington R. Depression, suicide and deliberate self-harm in adolescence. *Br. Med. Bull.* 2001;57:47-60.
- [19] Benjet C, Albor YC, Bocanegra ES, Borges G, Méndez E, Casanova L, et al. Incidence and recurrence of depression from adolescence to early adulthood: a longitudinal follow-up of the Mexican Adolescent Mental Health Survey. *J Affect. Disord.* 2019;263:540-6.
- [20] Benjet C, Borges G, Medina-Mora ME, Zambrano J, Aguilar-Gaxiola S. Youth mental health in a populous city of the developing world: results from the Mexican Adolescent Mental Health Survey. *J. Child Psychol. Psychiatry.* 2009;50(4):386-95.
- [21] Slone LB, Norris FH, Murphy AD, Baker CK, Perilla JL, Diaz D, et al. Epidemiology of major depression in four cities in Mexico. *Depress. Anxiety.* 2006;23(3):158-67.
- [22] Bridge JA, Goldstein TR, Brent DA. Adolescent suicide and suicidal behavior. *J. Child Psychol. Psychiatry.* 2006;47(3-4):372-94.
- [23] Borges G, Benjet C, Medina-Mora ME, Orozco R, Nock M. Suicide ideation, plan, and attempt in the Mexican adolescent mental health survey. *J. Am. Acad. Child Adolesc. Psychiatry.* 2008;47(1):41-52.
- [24] Costello EJ, Angold A, Burns BJ, Stangl DK, Tweed DL, Erkanli A, et al. The Great Smoky Mountains Study of Youth. Goals, design, methods, and the prevalence of DSM-III-R disorders. *Arch. Gen. Psychiatry.* 1996;53:1129-36.
- [25] Kashani J, Simonds JF. The incidence of depression in children. *Am. J. Psychiatry.* 1979;136(9):1203-5.
- [26] Garrison CZ, Waller JL, Cuffe SP, McKeown RE, Addy CL, Jackson KL. Incidence of major depressive disorder and dysthymia in young adolescents. *J. Am. Acad. Child Adolesc. Psychiatry.* 1997;36(4):458-65.
- [27] Instituto Nacional de Estadística y Geografía. INEGI. Org.mx. Available in: <https://www.inegi.org.mx/default.html>. Accessed 21/10/2021.
- [28] Zhao L, Han G, Zhao Y, Jin Y, Ge T, Yang W. Gender Differences in Depression: Evidence From Genetics. *Front. Genet.* 2020;11:562316.
- [29] Pataki CS, Carlson GA. Childhood and Adolescent Depression: A Review. *Harv. Rev. Psychiatry.* 1995;3(3):140-51.
- [30] Lamers F, van Oppen P, Comijs HC. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands study of depression and anxiety (NESDA). *J. Clin. Psychiatry.* 2011;72(3):341-8.
- [31] Matthew AR, Pettit JW, Lewinsohn PM, Seeley JR, Roberts RE. Comorbidity between major depression and anxiety disorders: shared etiology or direct causation? *Psychol. Med.* 2011;41(10):2023-34.
- [32] Kouider BE, Petermann F. Gemeinsame Risikofaktoren von depressiver und ängstlicher Symptomatik im Kindes und Jugendalter: ein systematisches Review aus transdiagnostischer Perspektive. *Fortschr. Neurol. Psychiatr.* 2015;83:321-33.
- [33] Nemeroff CB. Comorbidity of mood and anxiety disorders: The rule, not the exception?. *Am. J. Psychiatry.* 2002;159(1):3-4.
- [34] Roth M, Slater E. *Clinical Psychiatry.* Tindall and Cassell Limited. 3rd ed. London: Bailliere;1969.
- [35] Parker G, Hadzi-Pavlovic D, Brodaty H, Austin MP, Mitchell P, Wilhelm K, et al. Sub-typing depression, II. Clinical distinction of psychotic depression and non-psychotic melancholia. *Psychol. Med.* 1995;25(4):825-82.
- [36] Gadow KD, Sprafkin JM, Nolan E. DSM-IV symptoms in community and clinical preschool children. *J. Am. Acad. Child Adolesc. Psychiatry.* 2001;40(12):1383-92.
- [37] Axelson DA, Birmaher B. Relation between anxiety and depressive disorders in childhood and adolescence. *Depress. Anxiety.* 2001;14(2):67-78.
- [38] Zalsman G, Brent DA, Weersing VR. Depressive Disorders in Childhood and Adolescence: An Overview. *Child Adolesc. Psychiatric Clin. North. Am.* 2006;15:827-41.
- [39] Kovacs M. Presentation and course of major depressive disorder during childhood and later years of the life span. *J. Am. Acad. Child Adolesc. Psychiatry.* 1996;35:705-15.
- [40] Ihle W, Esser G, Laucht M, Schmidt MH. Depressive Störungen und aggressiv-dissoziale Störungen im Kindesund Jugendalter. *Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz.* 2004;47:728-35.
- [41] Ryan ND, Puig-Antich J, Ambrosini P, Rabinovich H, Robinson D, Nelson B, et al. The clinical picture of major depression in children and adolescents. *Arch. Gen. Psychiatry.* 1987;44(10):854-61.
- [42] Preiß M, Remschmidt H. Depressive Störungen im Kindes- und Jugendalter - Eine Übersicht. *Z. Kinder-Jugendpsychiatr. Psychother.* 2007;35(6):385-97.
- [43] Haug HJ. Affektive Störungen. In: H. J. Freyberger, R. D. Stieglitz. (Hrsg.), *Kompodium der Psychiatrie und Psychotherapie;* 1996.
- [44] Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H. Influence of life stress on depression: moderation by a polymorphism in the 5-HT gene. *Science.* 2003;301:386-89.
- [45] Mann JJ, Malone KM, Sweeney JA, Brown RP, Linnoila M, Stanley B et al. Attempted suicide characteristics and cerebrospinal fluid amine metabolites in depressed inpatients. *Neuropsychopharmacology.* 1996;15(6):576-86.
- [46] Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, et al. PET imaging of serotonin 1A receptor binding in depression. *Biol. Psychiatry.* 1999;46(10):1375-87.
- [47] Penza KM, Heim C, Nemeroff CB. Neurobiological effects of childhood abuse: implications for the pathophysiology of depression and anxiety. *Arch. Womens Men. Health.* 2003;6(1):15-22.
- [48] Saveanu RV, Nemeroff CB. Etiology of Depression: Genetic and Environmental Factors. *Psychiatric Clin. North. Am.* 2012;35(1):51-71.
- [49] Meyer JH, Krüger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A, et al. Lower dopamine transporter binding potential in striatum during depression. *Neuroreport.* 2001;12(18):4121-5.
- [50] Thombs BD, Roseman M, Kloda LA. Depression screening and mental health outcomes in children and adolescents: a systematic review protocol. *Systematic Reviews.* 2012;1(58).
- [51] President's New Freedom Commission on Mental Health: *Achieving the Promise: Transforming Mental Health Care in America - Final Report.* Department of Health and Human Services 2003.
- [52] Gomez Benumea RA. La Salud Mental como una Prioridad en la Agenda de la Salud Pública. *Educación y salud boletín científico de ciencias de la salud del ICSa (Internet).* Hidalgo 2016. Available in: <https://www.uaeh.edu.mx/scige/boletin/icsa/n8/e5.html>. Accessed 04/10/2021.
- [53] Gallego Iborra A. Cribado de depression mayor. *Prevencion en la infancia y la adolescencia (Internet).* Mexico 2020. Available in: <http://previnfad.aepap.org/monografia/depression>. Accessed 04/10/2021.

- [54] Uher R, Payne JL, Pavlova B, Perlis RH. Major depressive disorder in dsm-5: implications for clinical practice and research of changes from DSM-IV. *Depress. Anxiety*. 2013;31(6):459-71.
- [55] Rasing SP, Creemers DH, Janssens JM, Scholte RH. Effectiveness of depression and anxiety prevention in adolescents with high familial risk: study protocol for a randomized controlled trial. *BMC. Psychiatry*. 2013;13:316.
- [56] Beardslee WR, Brent DA, Weersing VR, Clarke GN, Porta G, Hollon SD, et al. Prevention of depression in at-risk adolescents: longer-term effects. *JAMA. Psychiatry*. 2013;70(11):1161-70.
- [57] Kovacs M, Paulauskas S, Gatsonis C, Richards C. Depressive disorders in childhood. III. a longitudinal study of comorbidity with and risk for conduct disorders. *J. Affect. Disord*. 1988;15(3):205-17.
- [58] Masia-Warner C, Nangle D, Hansen D. Bringing evidence-based child mental health services to the schools: general issues and specific populations. *Educ. Treat. Children*. 2006;29(2):165-72.
- [59] Ahlen J, Lenhard F, Ghaderi A. Universal Prevention for Anxiety and Depressive Symptoms in Children: A Meta-analysis of Randomized and Cluster-Randomized Trials. *J. Prim. Prev*. 2015;36(6):387-403.
- [60] Farberman D. Psicoterapia para niños y adolescentes. *Med Inf*. 2017;14(2):191-8.
- [61] Harrington R, Whittaker J, Shoebridge P, Campbell F. Systematic review of cognitive behavioral therapies in childhood and adolescent depressive disorder. *BMJ*. 1998;316:1559-63.
- [62] Weersing VR, Brent DA. Cognitive behavioral therapy for depression in youth. *Child Adolesc. Psychiatr. Clin. North. Am*. 2006;15(4):939-57.
- [63] Huot RL, Thirivikraman KV, Meaney MJ, Plotsky PM. Development of adult ethanol preference and anxiety as a consequence of neonatal maternal separation in Long Evans rats and reversal with antidepressant treatment. *Psychopharmacology*. 2001;158(4):366-73.
- [64] March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescent with depression. Treatment for Adolescent with Depression Study (TADS) randomized controlled trial. *JAMA*. 2004;292(7):807-20.
- [65] Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. *Arch. Gen. Psychiatry*. 1997;54(11):1031-7.
- [66] Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. *J. Am. Acad. Child Adolesc. Psychiatry*. 2002;41(10):1205-15.
- [67] Birmaher B, Brent D, Bernet W, Bukstein O, Walter H, Benson RS, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. *J. Am. Acad. Child Adolesc. Psychiatry*. 2007 Nov;46(11):1503-26.
- [68] Mendez X, Rosa AI, Montoya M, Espada JP, Olivares J, Sanchez-Meca J. Tratamiento psicologico de la depression infantil y adolescente: ¿Evidencia o promesa? *Psic. Conduc*. 2002;10(3):563-80.
- [69] Wagner K, Jonas J, Findling R, et al. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. *J. Am. Acad. Child Adolesc. Psychiatry*. 2006;45:280-8.
- [70] Emslie GJ, Wagner KD, Kutcher S, Krulewicz S, Fong R, Carpenter DJ, Lipschitz A, Machin A, Wilkinson C. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. *J. Am. Acad. Child Adolesc. Psychiatry*. 2006;45(6):709-719.
- [71] Pfalzgraf AR, Scott V, Makela E, Kavookjian J, Hartssock SL, Miller LA. Child psychiatrists' self-reported treatment and monitoring of children and adolescents with major depressive disorder. *J. Psychiatr. Pract*. 2012;18(4):253-61.
- [72] De Bellis MD, Nooner KB, Scheid JM, Cohen JA. Depression in Maltreated Children and Adolescents. *Child Adolesc. Psychiatr. Clin. North. Am*. 2019;28(3):289-302.
- [73] Tunnard C, Rane LJ, Wooderson SC, Markopoulou K, Poon L, Fekadu A, et al. The impact of childhood adversity on suicidality and clinical course in treatment-resistant depression. *J. Affect. Disord*. 2014;152-154:122-30.
- [74] Bodicherla KP, Shah K, Singh R, Arinze NC, Chaudhari G. School-Based Approaches to Prevent Depression in Adolescents. *Cureus*. 2021;13(2): e13443.